research: Halaven (eribulin) results for metastatic breast cancer

In a phase III clinical study Halaven® (eribulin) yielded statistically significant improvement in survival  for women with late-stage metastatic breast cancer.

Javier Cortes MD, Joyce O’Shaughnessy MD, David Loesch MD, Joanne L Blum MD, Linda T Vahdat MD, Katarina Petrakova MD, Philippe Chollet MD, Alexey Manikas MD, Veronique Diéras MD, Thierry Delozier MD, Vladimir Vladimirov MD, Fatima Cardoso MD, Han Koh MD, Philippe Bougnoux MD, Corina E Dutcus MD, Seth Seegobin MSc, Denis Mir MSc, Nicole Meneses MSHS, Jantien Wanders MD, Prof Chris Twelves MD. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. In The Lancet, Early Online Publication, 3 March 2011 doi:10.1016/S0140-6736(11)60070-6

5 6 7 8
© 2004-2011 Donna Peach. All rights reserved.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s